A Clinical Study Evaluating LY-M001 Injection in the Treatment of Adult Patients With Type I Gaucher Disease

Gaucher disease (GD) is caused by mutations in the GBA1 gene, which leads to a lack or reduction of GCase activity. The consequences of this deficiency are generally attributed to the accumulation of the GCase substrate, Glucosylceramide (GlcCer), in macrophages in the liver, spleen, kidney, bone, lung, and even the brain, inducing their transformation into Gaucher cells whose cell cytoplasm presenting a characteristic "crumpled tissue paper" appearance, leading to pathological changes in involved tissues and organs.LY-M001 Injection is an rAAV8 vector gene therapy product. It can specifically transduce the target organ liver after a single intravenous administration and express the GCase protein in liver cells for a long period of time.

NCT Number	NCT06818838
Lead Sponsor	Lingyi Biotech Co., Ltd.
Conditions	Gaucher Disease Type 1
Enrollment	12 participants
Start Date	2024-07-05
Primary Completion	2027-07-30 (estimated)
Study Completion	2031-07-30 (estimated)
Updated on ClinicalTrials.gov	2026-01-26